Blue skies for bluebird

Deerfield Partners made a rare investment in a private company last week when the hedge fund participated in gene therapy company bluebird bio Inc.'s $60 million series D round.

Deerfield only makes about two investments in private companies a year. The firm's Howard Furst told BioCentury it "tends to invest privately when we know management and know the disease space well."...